Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients

Kidney International

Volumn 42, Issue 5, 1992, Pages 1191-1198

  Gallieni, Maurizio ^b   Brancaccio, Diego ^a   Padovese, Paola ^b   Rolla, Davide ^b   Bedani, Pierluigi ^b   Colantonio, Giuseppe ^b   Bronzieri, Claudio ^b   Bagni, Bruno ^b   Tarolo, Gianluigi ^b  

^a SAN PAOLO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG SAFETY; HEMODIALYSIS; HORMONE RELEASE; HUMAN; HYPERPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; ADULT; AGED; CALCITRIOL; CALCIUM; HUMAN; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; MIDDLE AGE; PARATHYROID HORMONES; PHOSPHATES; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T;

EID: 0026785324     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1992.404     Document Type: Article

References (36)

1. FRASER DR, KODICEK E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764-766, 1970
2. BERL T, BERNS AS, HUFFER WE, HAMMILL K, ALFREY AC, ARNAUD CD, SCHRIER RW: 1,25-Dihydroxycholecalciferol effects in chronic dialysis: A double-blind controlled study. Ann Intern Med 88:774-780, 1978
3. MADSEN S, OLGAARD K: Long-term trial of 1α-hydroxycholecalciferol in adults with chronic renal failure. Eur J Clin Pharmacol 13:401-408, 1978
4. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S, NORWOOD K, LINK M, WINDUS D, DELMEZ J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
5. 3 of transcription of the parathyroid hormone gene. Endocrinology 119:2864-2866, 1986
6. SILVER J, NAVEH-MANY T, MAYER H, SCHMEIZER HJ, POPOVTZER MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296-1301, 1986
7. SLATOPOLSKY E, WEERTS C, THIELAN J, HORST R, HARTER H, MARTIN KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
8. ANDRESS DL, NORRIS KC, COBURN JW, SLATOPOLSKY EA, SHERRARD DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
9. 3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 117:2114-2119, 1985
10. 2D. A role for increased sensitivity to calcium. J Clin Invest 83:1349-1355, 1989
11. 3. Nephron 58:288-294, 1991
12. NUSSBAUM SR, ZAHRADNIK RJ, LAVIGNE JR, BRENNAN GL, NOZAWA-UNG K, KIM LY, KEUTMANN HT, WANG CA, POTTS JT, SEGRE GV: Highly sensitive two-sites immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367, 1987
13. MALLETTE LE, TUMA SN, BERGER RE, KIRKLAND JL: Radioimmunoassay for the middle region of human parathyroid hormone using an homologous antiserum with a carboxyl-terminal fragment of bovine parathyroid hormone as radioligand. J Clin Endocrinol Metab 54:1017-1024, 1982
14. SALUSKY IB, GOODMAN WG, NORRIS KC, HORST R, FINE RN, COBURN JW: Bioavailability of calcitriol after oral, intravenous and intraperitoneal doses in dialysis patients, in Vitamin D. Molecular, Cellular and Clinical Endocrinology, edited by AW NORMAN, K SHEAFER, HG GRIGOLEIT, DV HERRATH, Berlin, Walter de Gruyter and Co., 1988, pp. 783-784
15. QUARLES LD, DAVIDAI GA, SCHWAB SJ, BARTHOLOMAY DW, LABAUGH B: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 34:840-844, 1988
16. CHERTOW BS, BAYLINK DJ, WERGEDAL JE, SU MH, NORMAN AW: Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1.25-dihydroxycholecalciferol. J Clin Invest 56:668-678, 1975
17. CHAN YL, MCKAY C, DYE E, SLATOPOLSKY E: The effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion from bovine parathyroid cells. Calcif Tissue Int 38:27-32, 1986
18. NORRIS KC, KRAUT JA, ANDRESS DL, AGRE KL, SHERRARD DJ, COBURN JW: Intravenous calcitriol: Effects in severe secondary hyperparathyroidism. (abstract) J Bone Miner Res 1(Suppl):374, 1986
19. GARRICK R, KUMAR U, FALLON M, DICARLO E: The efficacy of intravenous and oral calcitriol in the treatment of renal osteodystrophy. (abstract) J Am Soc Nephrol 2:610, 1991
20. GONZALEZ E, BANDER S, THIELAN B, MARTIN KJ: Comparison of intravenous and pulse oral calcitriol for suppression of PTH in patients on hemodialysis. (abstract) J Am Soc Nephrol 2:636, 1991
21. DUNLAY R, RODRIGUEZ M, FELSENFELD AJ, LLACH F: Direct inhibitory effect of calcitriol on parathyroid function (Sigmoidal curve) in dialysis. Kidney Int 36:1093-1098, 1989
22. RODRIGUEZ M, FELSENFELD AJ, WILLIAMS C. PEDERSON JA, LLACH F: The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2:1014-1020, 1991
23. SLATOPOLSKY E, WEERTS C, NORWOOD K, GILES K, FRYER P, FINCH J, WINDUS D, DELMEZ J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897-903, 1989
24. YUDIS M, SIROTA R, STEIN H: Rapid metastatic calcification with intravenous calcitriol therapy. National Kidney Foundation, 18th Annual Scientific Meeting (abstract). 1988, pp A22
25. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35:1049-1056, 1989
26. FUKAGAWA M, KANAME SY, IGARASHI T, OGATA E, KUROKAWA K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 39:874-881, 1991
27. 3. J Biol Chem 258:2100-2107, 1983
28. ANDRESS DL, OTT SM, MALONEY NA, SHERRARD DJ: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468-473, 1985
29. MILLINER DS, NEBEKER HG, OTT SM, ANDRESS DL, SHERRARD DJ, ALFREY AC, SLATOPOLSKY EA, COBURN JW: Use of the deferoxamine infusion test in the diagnosis of aluminum related osteodystrophy. Ann Intern Med 101:775-780, 1984
30. GILLI P, MALACARNE F, STORARI A, BRANCACCIO D, GALLIENI M, ANDRIANI M, PICCOLI A, NORDIO M: Desferrioxamine infusion test. Nephrol Dial Transplant 2:54-55, 1987
31. SLATOPOLSKY E, LOPEZ-HILKER S, DUSSO A, BROWN A, DELMEZ J, MARTIN K: Renal osteodystrophy: Past and future, in Terminal Renal Failure: Therapeutic Problems, Possibilities, and Potentials, edited by H KLINKMAN and LC SMEBY, Basel, Karger, Contrib Nephrol 78:38-46, 1990
32. COBURN JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38(Suppl):S54-S61, 1990
33. MOORTHY AV, HARRINGTON AR, MAZESS RB, SIMPSON DP: Long-term therapy of uremic osteodystrophy in adults with calcitriol. Clin Nephrol 16:93-100, 1981
34. BROWN AJ, FINCH JL, LOPEZ-HILKER S, DUSSO A, RITTER C, PERNALETE N, SLATOPOLSKY E: New active analogues of vitamin D with low calcemic activity. Kidney Int 38(Suppl 29):S22-S27, 1990
35. 3 intake: Emergence of an idiopathic adynamic bone disease net related to aluminum. Nephron 53:93-101, 1989
36. FUKAGAWA M, YI H, KUROKAWA K: Calcitriol induces apoptosis of hyperplastic parathyroid cells in uremic rats. (abstract) J Am Soc Nephrol 2:635, 1991